gms | German Medical Science

57. Jahrestagung der Deutschen Gesellschaft für Neuropathologie und Neuroanatomie (DGNN)

Deutsche Gesellschaft für Neuropathologie und Neuroanatomie

12. - 15.09.2012, Erlangen

Banner: 57. Jahrestagung der Deutschen Gesellschaft für Neuropathologie und Neuroanatomie

Artikel

Artikel empfehlen

Anti-tissue factor (TF9-10H10) treatment reduces tumor cell invasiveness in a novel migratory glioma model

Meeting Abstract

Suche in Medline nach

  • presenting/speaker Patrick N. Harter - Goethe University Frankfurt, Edinger Institute (Neurological Institute), Frankfurt, Germany
  • Stephan Dützmann - Experimental Neurosurgery, Center for Neurology and Neurosurgery, Frankfurt, Germany
  • Ulrich Drott - Goethe University Frankfurt, Edinger Institute (Neurological Institute), Frankfurt, Germany
  • Elke Hattingen - Department of Neuroradiology, Goethe University Frankfurt, Frankfurt, Germany
  • David Capper - Institute of Neuropathology, Heidelberg, Germany; Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany
  • Florian Gessler - Experimental Neurosurgery, Center for Neurology and Neurosurgery, Frankfurt, Germany
  • Christian Senft - Experimental Neurosurgery, Center for Neurology and Neurosurgery, Frankfurt, Germany
  • Volker Seifert - Experimental Neurosurgery, Center for Neurology and Neurosurgery, Frankfurt, Germany
  • Karl-Heinz Plate - Goethe University Frankfurt, Edinger Institute (Neurological Institute), Frankfurt, Germany
  • Donat Kögel - Experimental Neurosurgery, Center for Neurology and Neurosurgery, Frankfurt, Germany
  • Michel Mittelbronn - Goethe University Frankfurt, Edinger Institute (Neurological Institute), Frankfurt, Germany

Deutsche Gesellschaft für Neuropathologie und Neuroanatomie. 57th Annual Meeting of the German Society for Neuropathology and Neuroanatomy (DGNN). Erlangen, 12.-15.09.2012. Düsseldorf: German Medical Science GMS Publishing House; 2012. Doc12dgnnPP5.9

doi: 10.3205/12dgnn109, urn:nbn:de:0183-12dgnn1095

Veröffentlicht: 11. September 2012

© 2012 Harter et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.

Gliederung

Text

In vitro and descriptive studies of human tissue samples revealed the pro-coagulant glycoprotein tissue factor (TF) as a potent player in glioma cell infiltration that is activated by hypoxia and has also been shown to be upregulated by mutations of TP53 or PTEN. In the present study, we established a murine xenograft treatment model by transplanting the angiogenic and diffusely infiltrating human glioma cell line MZ-18 with endogenous TF expression into nude mice brains and treating these mice with a novel intracranial osmotic pump system continuously infusing a monoclonal antibody against TF (mAb TF9-10H10). The human MZ-18 cell line harbours two homozygous TP53 mutations resulting in a strong nuclear accumulation of p53 thereby facilitating the unambiguous identification of tumor cells in the xenograft model. Intracranial application of TF9-10H10 significantly reduced invasion of MZ-18 cells compared to mock treated control animals. The extent of activated blood vessels was also reduced upon anti-TF treatment. In conclusion, targeting the tissue factor pathway might be a promising treatment strategy for future glioblastoma therapies.